Clinical trials: Adolescent Asthma
Asthma
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
- Trial name
- NCT00482248
- Testing
- Omalizumab
- Volunteers
- 132 people
- Sponsor
- Novartis
Asthma
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Approximately 480 (120 per group) would need to complete the 12 weeks of treatments.
- Trial name
- NCT03835871
- Testing
- 400 µg per day Beclomethasone, 200 µg per day Beclomethasone, 100 µg per day Beclomethasone
- Sponsor
- Adamis Pharmaceuticals Corporation